AU2017332367B2 - High mobility group box i mutant - Google Patents

High mobility group box i mutant Download PDF

Info

Publication number
AU2017332367B2
AU2017332367B2 AU2017332367A AU2017332367A AU2017332367B2 AU 2017332367 B2 AU2017332367 B2 AU 2017332367B2 AU 2017332367 A AU2017332367 A AU 2017332367A AU 2017332367 A AU2017332367 A AU 2017332367A AU 2017332367 B2 AU2017332367 B2 AU 2017332367B2
Authority
AU
Australia
Prior art keywords
seq
vaccinia virus
virus
pfu
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017332367A
Other languages
English (en)
Other versions
AU2017332367A1 (en
Inventor
Stephen H. Thorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2017332367A1 publication Critical patent/AU2017332367A1/en
Application granted granted Critical
Publication of AU2017332367B2 publication Critical patent/AU2017332367B2/en
Priority to AU2022200169A priority Critical patent/AU2022200169B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017332367A 2016-09-21 2017-09-21 High mobility group box i mutant Ceased AU2017332367B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200169A AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662397523P 2016-09-21 2016-09-21
US62/397,523 2016-09-21
PCT/US2017/052746 WO2018057755A1 (en) 2016-09-21 2017-09-21 High mobility group box i mutant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200169A Division AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Publications (2)

Publication Number Publication Date
AU2017332367A1 AU2017332367A1 (en) 2019-04-11
AU2017332367B2 true AU2017332367B2 (en) 2021-12-23

Family

ID=61691108

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017332367A Ceased AU2017332367B2 (en) 2016-09-21 2017-09-21 High mobility group box i mutant
AU2022200169A Expired - Fee Related AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200169A Expired - Fee Related AU2022200169B2 (en) 2016-09-21 2022-01-12 High mobility group box i mutant

Country Status (7)

Country Link
US (2) US11065286B2 (https=)
EP (1) EP3515419A4 (https=)
JP (1) JP2019528753A (https=)
KR (1) KR20190059297A (https=)
CN (1) CN110022867A (https=)
AU (2) AU2017332367B2 (https=)
WO (1) WO2018057755A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
JP7025339B2 (ja) 2016-02-25 2022-02-24 メモリアル スローン ケタリング キャンサー センター 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
US11345896B2 (en) 2016-11-02 2022-05-31 David Evans Synthetic chimeric poxviruses
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
CN117004573A (zh) * 2017-12-13 2023-11-07 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
WO2019143201A1 (ko) * 2018-01-19 2019-07-25 코오롱생명과학 주식회사 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
BR112020022181A2 (pt) 2018-05-02 2021-02-09 Tonix Pharma Holdings Limited vírus vaccinia quimérico sintético
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
US20220288143A1 (en) * 2019-08-29 2022-09-15 Bionoxx Inc. Pharmaceutical composition for treating cancer, comprising vaccinia virus and granulopoiesis inhibitor as active ingredients
CA3197371A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
AU2023363981A1 (en) * 2022-10-19 2025-05-01 Kalivir Immunotherapeutics, Inc. Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285860A1 (en) * 2008-04-04 2009-11-19 The General Hospital Corporation Cancer immunotherapy
EP2703487A1 (en) * 2011-04-26 2014-03-05 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
US20160235793A1 (en) * 2013-08-22 2016-08-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-Oncolytic Therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269619A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
US20090136917A1 (en) * 2007-10-25 2009-05-28 Szalay Aladar A Systems and methods for viral therapy
WO2012036215A1 (ja) * 2010-09-17 2012-03-22 Taniguchi Tadatsugu Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
FI20115914A7 (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285860A1 (en) * 2008-04-04 2009-11-19 The General Hospital Corporation Cancer immunotherapy
EP2703487A1 (en) * 2011-04-26 2014-03-05 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
US20160235793A1 (en) * 2013-08-22 2016-08-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-Oncolytic Therapies

Also Published As

Publication number Publication date
WO2018057755A1 (en) 2018-03-29
US11065286B2 (en) 2021-07-20
EP3515419A4 (en) 2020-06-10
AU2022200169B2 (en) 2025-05-29
US20190209629A1 (en) 2019-07-11
US20210338754A1 (en) 2021-11-04
KR20190059297A (ko) 2019-05-30
AU2017332367A1 (en) 2019-04-11
CN110022867A (zh) 2019-07-16
JP2019528753A (ja) 2019-10-17
AU2022200169A1 (en) 2022-02-10
EP3515419A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
AU2022200169B2 (en) High mobility group box i mutant
US12246049B2 (en) Oncolytic viruses targeting STAT3
US12318419B2 (en) Platform oncolytic vector for systemic delivery
US20250249054A1 (en) Methods of Treating Cancer
US20220049228A1 (en) Modified Extracellular Enveloped Virus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired